MRI contrast agent developer Epix Medical reported revenues of $1.6 million in its third quarter, compared with revenues of $70,000 during the same period in 1999. For the quarter (end-September 30), the Cambridge, MA-based firm had a net loss of $4.6 million, compared with a net loss of $4.6 million last year. Epix’s third-quarter revenues were derived from product development contracts with Schering, according to the company.
By AuntMinnie.com staff writersOctober 20, 2000
Related Reading
Epix to secure $45 million in financing, September 19, 2000
Epix net loss widens despite Q2 revenue surge, July 21, 2000
Schering, Epix, Mallinckrodt exchange rights for cardiac MRI agent, June 9, 2000
Epix, Schering end patent dispute, May 9, 2000
Copyright © 2000 AuntMinnie.com
